Literature DB >> 7802732

Screening for lung cancer re-examined. A reinterpretation of the Mayo Lung Project randomized trial on lung cancer screening.

G M Strauss1, R E Gleason, D J Sugarbaker.   

Abstract

In the 1970s, three randomized trials, each involving approximately 10,000 male subjects, were carried out to determine the value of lung cancer screening in cigarette smokers. These studies have been widely interpreted as providing strong evidence that screening does not contribute to decreased death rates, and, accordingly, the American Cancer Society firmly recommends against lung cancer screening. No randomized trial, however, has evaluated screening for lung cancer in women, who currently comprise 39% of the lung cancer population. The trials performed at Memorial-Sloan Kettering and at Johns Hopkins were designed so that subjects were randomized to either a single screen (annual chest x-ray alone) or a dual screen (annual chest x-ray and every-4-month sputum cytology) group. While the results of both revealed no difference in mortality between the groups, these studies were designed to examine the value of sputum cytology, and no conclusion regarding the efficacy of chest x-rays can be inferred. In the Mayo Lung Project, patients were randomized to a screened group in which a chest x-ray and sputum cytology were obtained every 4 months or to a control group in which an annual chest x-ray and cytology were simply recommended. The results indicate that after 6 years, more lung cancers were detected among the 4,618 men in the screened group (206 cases, 4.46%) than in the 4,593 men in the control group (160 cases, 3.48%). The screened group showed a superiority over the control subjects in resectability rate (46% vs 32%) and 5-year survival (33% vs 15%). However, the number of cancer deaths was slightly greater in the screened (122) than in the control group (115), and, consequently, the mortality rates were not significantly different among the groups. An "overdiagnosis bias" has been suggested to account for the increased number of lung cancers detected in the screened vs the control population in the Mayo Lung Project. This explanation is statistically plausible, but, given the status of lung cancer as the most lethal of malignancies, is biologically unlikely. An alternative hypothesis is that chance alone might have accounted for the observed 0.98% difference in lung cancer detection rates. Were this the case, then 46 additional cases would have been detected in the control group had this chance event not occurred.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 7802732

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Evaluating randomized trials of screening.

Authors:  H G Welch; W C Black
Journal:  J Gen Intern Med       Date:  1997-02       Impact factor: 5.128

2.  Value of the chest radiograph before cardiac catheterisation in adults.

Authors:  M Pearson; C Layton
Journal:  Br Heart J       Date:  1994-12

Review 3.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

4.  Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai.

Authors:  Xiaoyang Luo; Shanbo Zheng; Quan Liu; Shengping Wang; Yuan Li; Lei Shen; Guodong Li; Wentao Li; Yanping Zhao; Huilin Xu; Jing Wang; Xiaohua Liu; Yunjian Pan; Hong Hu; Yihua Sun; Haiyan Yang; Su Xu; Haiquan Chen
Journal:  Transl Oncol       Date:  2017-05-15       Impact factor: 4.243

Review 5.  [Advance of lung cancer screening with low-dose spiral CT].

Authors:  Guanhua Ren; Yaguang Fan; Yongcheng Zhao; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-10-20

6.  Lung Nodule Malignancy Prediction in Sequential CT Scans: Summary of ISBI 2018 Challenge.

Authors:  Yoganand Balagurunathan; Andrew Beers; Michael Mcnitt-Gray; Lubomir Hadjiiski; Sandy Napel; Dmitry Goldgof; Gustavo Perez; Pablo Arbelaez; Alireza Mehrtash; Tina Kapur; Ehwa Yang; Jung Won Moon; Gabriel Bernardino Perez; Ricard Delgado-Gonzalo; M Mehdi Farhangi; Amir A Amini; Renkun Ni; Xue Feng; Aditya Bagari; Kiran Vaidhya; Benjamin Veasey; Wiem Safta; Hichem Frigui; Joseph Enguehard; Ali Gholipour; Laura Silvana Castillo; Laura Alexandra Daza; Paul Pinsky; Jayashree Kalpathy-Cramer; Keyvan Farahani
Journal:  IEEE Trans Med Imaging       Date:  2021-11-30       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.